PHARMA LITERATI

Call it opportunistic volume gain at better margins or seeking new growth options under adverse market conditions. Either way, some of the leading Indian pharma companies are pitching in to cater to the markets that some of the big global pharma companies are vacating as part of their product optimisation strategies. They are also pitching in to fill in for the temporary shortages that some of the companies have caused due to issues such as regulatory challenges their plants face. Agile companies that can meet this gap and in turn expand their market share see this as an opportunity. One such company is Hyderabad-based Aurobindo Pharma , which has even given it a name 'New Business Opportunity'. The move, apparently, is yielding results. Aurobindo has received an opportunity to supply an incremental volume worth $90 million to $100 million over a span of 12 to 15 months starting second quarter of FY18. In fact, the company has also been building capacities so that i...

Hyderabad-based pharma co may spend $200 m on Generis, which has a presence across anti-infective, anti-diabetes & dermatology drugs Hyderabad-based Aurobindo Pharma has expressed preliminary interest in acquiring Portuguese drug maker Generis Farmaceutica for about $200 million. Generis has a presence across anti-infective, respiratory, anti-diabetes and dermatology drugs and sells to hospitals, clinics and pharmacies besides having a contract manufacturing and analytical services arm. Aurobindo's latest bid comes on the heels of an earlier shot at Israeli-drug maker Teva's UK product portfolio, where it was outbid by rival Intas Pharmaceuticals last month. The family-owned Ahmedabad company paid a whopping $764 million to bolster its European operations. Aurobindo's move to buy the Portuguese firm is seen as resurrection of an earlier interest after its Teva chase was foiled.The Generis deal is on the table for the past few months, it fits Aurobindo...